Search

Your search keyword '"Angelopoulou, Maria K."' showing total 635 results
Start Over Author "Angelopoulou, Maria K."
635 results on '"Angelopoulou, Maria K."'

52. Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP

Author

Vassilakopoulos, Theodoros P., primary, Michail, Michail, additional, Papageorgiou, Sotirios, additional, Kourti, Georgia, additional, Angelopoulou, Maria K., additional, Panitsas, Fotios, additional, Sachanas, Sotirios, additional, Kalpadakis, Christina, additional, Katodritou, Eirini, additional, Leonidopoulou, Theoni, additional, Kotsianidis, Ioannis, additional, Hatzimichael, Eleftheria, additional, Kotsopoulou, Maria, additional, Dimou, Maria, additional, Variamis, Eleni, additional, Boutsis, Dimitrios, additional, Terpos, Evangelos, additional, Dimopoulou, Maria N., additional, Karakatsanis, Stamatios, additional, Michalis, Eurydiki, additional, Karianakis, George, additional, Tsirkinidis, Pantelis, additional, Vadikolia, Chryssa, additional, Poziopoulos, Christos, additional, Pigaditou, Anna, additional, Vrakidou, Effimia, additional, Economopoulos, Theophanis, additional, Kyriazopoulou, Lydia, additional, Siakantaris, Marina P., additional, Kyrtsonis, Marie-Christine, additional, Symeonidis, Argyris, additional, Anargyrou, Konstantinos, additional, Papaioannou, Maria, additional, Hatjiharissi, Evdoxia, additional, Vervessou, Elissavet, additional, Tsirogianni, Maria, additional, Palassopoulou, Maria, additional, Gainaru, Gabriella, additional, Stefanoudaki, Ekaterini, additional, Zikos, Panayiotis, additional, Tsirigotis, Panayiotis, additional, Tsourouflis, Gerasimos, additional, Assimakopoulou, Theodora, additional, Konstantinidou, Pavlina, additional, Papadaki, Helen A., additional, Megalakaki, Katerina, additional, Dimopoulos, Meletios-Athanasios, additional, Pappa, Vassiliki, additional, Karmiris, Themis, additional, Roussou, Paraskevi, additional, Panayiotidis, Panayiotis, additional, Konstantopoulos, Kostas, additional, and Pangalis, Gerassimos A., additional

Published
2021
Full Text
View/download PDF

53. Pancytopenia, eosinophilia and coagulation disorders in a patient with T‐acute lymphoblastic leukemia in prolonged remission

Author

Chatzidimitriou, Chrysovalantou, primary, Pappa, Vasiliki, additional, Lakiotaki, Eleftheria, additional, Plata, Eleni, additional, Lafioniatis, Stylianos, additional, Angelopoulou, Maria K., additional, Konstantopoulos, Kostas, additional, Korkolopoulou, Penelope, additional, and Vassilakopoulos, Theodoros P., additional

Published
2021
Full Text
View/download PDF

54. Evaluation of automated capillary complete blood counts for routine clinical decision making in a large cohort of hematological patients, using Mindray BC-3000 Plus Auto and Sysmex XE-5000 hematology analyzers

Author

Oudatzis, Georgios Tsagarakis, Nikolaos J. Paterakis, Georgios and Vasileiou, Paraskevi Xenou, Efthalia Maraki, Paraskevi and Pangrati, Toula Angelopoulou, Maria K. Vassilakopoulos, Theodoros P. Konstantopoulos, Kostas

Abstract

Introduction Venous blood (VB) sampling for complete blood count (CBC) via venipuncture is the basic method for the daily evaluation of hematological patients. However, several issues during this process, such as venipuncture difficulty and repetitive attempts, may cause pain, phlebitis, hematomas, inadequate sampling, and patient discomfort. Capillary blood (CB) sampling could be an alternative and less painful solution for the patient. The purpose of this study was the comparative evaluation of basic CBC parameters, as counted from venous and capillary blood samples. Methods During the period 06/2016-06/2019 in which the study was conducted, 1634 automated counts of VB or CB were performed, derived from 425 hematological hospitalized patients. Bland-Altman plots were performed to show the agreement of VB and CB counts of common hematological parameters (Hb, Hct, WBC, absolute neutrophil count-[ANC], RBC, Plt, MCV, MCH), using two different hematology analyzers (Mindray BC-3000 Plus Auto and Sysmex XE-5000). Clinical significance of CB sampling was assessed by applying specific clinically significant cutoffs for Hb, ANC, and Plt. Results All measured parameters revealed a significant correlation (r > .9) between CB and VB samples, irrelatively of the hematology analyzer used. CB measurements of Hb, ANC, and Plt, at different clinically important cutoff levels, showed excellent sensitivity (87%-100%), specificity (95%-100%), positive predictive value, and negative predictive value (87%-100% and 90%-100%, respectively). Conclusion Capillary blood and VB counts in hematological patients were equivalent for most basic hematological parameters. Hb, ANC, and Plt CB counts revealed clinically significant performance, indicating that they can reliably substitute VB sampling in the day work.

Published
2020

55. Optimizing outcomes in relapsed/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategies

Author

Vassilakopoulos, Theodoros P. Asimakopoulos, John V. and Konstantopoulos, Kostas Angelopoulou, Maria K.

Abstract

The outcome of patients with relapsed/refractory classical Hodgkin lymphoma (rr-cHL) has improved considerably in recent years owing to the approval of highly active novel agents such as brentuximab vedotin and Programmed Death-1 (PD-1) inhibitors. Although no randomized trials have been conducted to provide formal proof, it is almost undisputable that the survival of these patients has been prolonged. As autologous stem-cell transplantation (SCT) remains the standard of care for second-line therapy of most patients with rr-cHL, optimization of second-line regimens with the use of brentuximab vedotin, or, in the future, checkpoint inhibitors, is promising to increase both the eligibility rate for transplant and the final outcome. The need for subsequent therapy, and especially allogeneic SCT, can be reduced with brentuximab vedotin consolidation for 1 year, while pembrolizumab is also being tested in this setting. Several other drug categories appear to be active in rr-cHL, but their development has been delayed by the appearance of brentuximab vedotin, nivolumab and pembrolizumab, which have dominated the field of rr-cHL treatment in the last 5 years. Combinations of active drugs in chemo-free approaches may further increase efficacy and hopefully reduce toxicity in rr-cHL, but are still under development.

Published
2020

56. Real‐life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B‐cell lymphomas

Author

Dimou, Maria, primary, Papageorgiou, Sotirios G., additional, Stavroyianni, Niki, additional, Katodritou, Eirini, additional, Tsirogianni, Maria, additional, Kalpadakis, Christina, additional, Banti, Anastasia, additional, Arapaki, Maria, additional, Iliakis, Theodoros, additional, Bouzani, Maria, additional, Verrou, Eugenia, additional, Spanoudakis, Emmanouil, additional, Giannouli, Stavroula, additional, Marinakis, Theodoros, additional, Mandala, Evdokia, additional, Mparmparousi, Despoina, additional, Sachanas, Sotirios, additional, Dalekou‐Tsolakou, Maria, additional, Hatzimichael, Eleftheria, additional, Vadikolia, Chryssa, additional, Violaki, Vasiliki, additional, Poziopoulos, Christos, additional, Tsirkinidis, Pantelis, additional, Chatzileontiadou, Sofia, additional, Vervessou, Elissavet, additional, Ximeri, Maria, additional, Sioni, Anastasia, additional, Konstantinidou, Pavlina, additional, Kyrtsonis, Marie‐Christine, additional, Siakantaris, Marina P., additional, Angelopoulou, Maria K., additional, Pappa, Vassiliki, additional, Konstantopoulos, Kostas, additional, Panayiotidis, Panayiotis, additional, and Vassilakopoulos, Theodoros P., additional

Published
2021
Full Text
View/download PDF

57. Expression of the novel tumour suppressor sterile alpha motif and HD domain‐containing protein 1 is an independent adverse prognostic factor in classical Hodgkin lymphoma

Author

Xagoraris, Ioanna, primary, Vassilakopoulos, Theodoros P., additional, Drakos, Elias, additional, Angelopoulou, Maria K., additional, Panitsas, Fotios, additional, Herold, Nikolas, additional, Medeiros, L. Jeffrey, additional, Giakoumis, Xanthoula, additional, Pangalis, Gerassimos A., additional, and Rassidakis, George Z., additional

Published
2021
Full Text
View/download PDF

58. Curative surgery in highly selected patients with heavily pretreated, relapsed/refractory classical Hodgkin lymphoma

Author

Papadakis, Vassilios, primary, Efstathopoulou, Maria, additional, Angelopoulou, Maria K., additional, Tsourouflis, Gerassimos, additional, Prassopoulos, Vassilios, additional, Rondogianni, Phivi, additional, Kourtesis, Antonios, additional, Polychronopoulou, Sophia, additional, Pangalis, Gerassimos A., additional, and Vassilakopoulos, Theodoros P., additional

Published
2020
Full Text
View/download PDF

59. Successful salvage of primary progressive Hodgkin lymphoma with the combination of post‐transplant brentuximab vedotin and radiotherapy: Combining novelty and tradition

Author

Belia, Marina, primary, Chatzidimitriou, Chrysovalantou, additional, Rondogianni, Phivi, additional, Petsa, Panayiota, additional, Efstathopoulou, Maria, additional, Konstantinou, Eliana, additional, Arapaki, Maria, additional, Asimakopoulos, John, additional, Plata, Eleni, additional, Konstantopoulos, Kostas, additional, Angelopoulou, Maria K., additional, and Vassilakopoulos, Theodoros P., additional

Published
2020
Full Text
View/download PDF

60. Validation of the simplified International Prognostic Score3 in a Hellenic cohort of patients with advanced‐stage Hodgkin‐lymphoma

Author

Asimakopoulos, John V., primary, Angelopoulou, Maria K., additional, Arapaki, Maria‐Panagiota, additional, Kanellopoulos, Alexandros, additional, Dimou, Maria, additional, Giakoumis, Xanthoula, additional, Konstantinou, Eliana, additional, Belia, Marina, additional, Chatzidimitriou, Chrysovalantou, additional, Sachanas, Sotirios, additional, Iliakis, Theodoros, additional, Kyrtsonis, Marie‐Christine, additional, Siakantaris, Marina P., additional, Viniou, Nora‐Athina, additional, Variamis, Eleni, additional, Kontopidou, Flora N., additional, Pangalis, Gerassimos A., additional, Panayiotidis, Panayiotis, additional, Konstantopoulos, Kostas, additional, and Vassilakopoulos, Theodoros P., additional

Published
2020
Full Text
View/download PDF

61. Evaluation of automated capillary complete blood counts for routine clinical decision making in a large cohort of hematological patients, using Mindray BC‐3000 Plus Auto and Sysmex XE‐5000 hematology analyzers

Author

Oudatzis, Georgios, primary, Tsagarakis, Nikolaos J., additional, Paterakis, Georgios, additional, Vasileiou, Paraskevi, additional, Xenou, Efthalia, additional, Maraki, Paraskevi, additional, Pangrati, Toula, additional, Angelopoulou, Maria K., additional, Vassilakopoulos, Theodoros P., additional, and Konstantopoulos, Kostas, additional

Published
2020
Full Text
View/download PDF

65. Development and validation of a clinical prediction rule for bone marrow involvement in patients with Hodgkin lymphoma

Author

Vassilakopoulos, Theodoros P., Angelopoulou, Maria K., Constantinou, Nikos, Karmiris, Themistoklis, Repoussis, Panayiotis, Roussou, Paraskevi, Siakantaris, Marina P., Korkolopoulou, Penelope, Kyrtsonis, Marie-Christine, Kokoris, Styliani I., Dimopoulou, Maria N., Variamis, Eleni, Viniou, Nora-Athina, Konstantopoulos, Konstantinos, Dimitriadou, Evangelia M., Androulaki, Athina, Patsouris, Efstratios, Doussis-Anagnostopoulou, Ipatia A., Panayiotidis, Panayiotis, Boussiotis, Vassiliki A., Kittas, Christos, and Pangalis, Gerassimos A.

Published
2005
Full Text
View/download PDF

67. Primary Bone Non-Hodgkin's Lymphoma: A Specific Clinical Entity with Aggressive Clinical Course and High Cure Rate - Retrospective Analysis of 102 Patients from Greece

Author

Symeonidis, Argiris Papageorgiou, Sotirios Patrinos, Antonis and Melachrinou, Maria Kourakli, Alexandra Pappa, Vassiliki and Angelopoulou, Maria K. Sioni, Anastasia Kanellias, Nikolaos and Chatzileontiadou, Sofia Hatzimichael, Eleftheria Zikos, Panagiotis Pouli, Anastasia Papaioannou, Maria Terpos, Evangelos Pangalis, Gerasimos Vassilakopoulos, Theodoros P.

Published
2019

69. Bone Loss and High Bone Turnover in Patients with Non-Hodgkin's Lymphoma Who Receive Frontline Chemotherapy: Final Results of a Multicenter Prospective Study

Author

Terpos, Evangelos Fotiou, Despina Anargyrou, Konstantinos and Vassilakopoulos, Theodoros P. Christoulas, Dimitrios Makras, Polyzois Dimou, Maria Ntanasis-Stathopoulos, Ioannis and Masouridou, Stavroula Angelopoulou, Maria K. Papatheodorou, Athanasios Tsionos, Konstantinos Panayiotidis, Panayiotis and Dimopoulos, Meletios A.

Published
2019

70. Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma

Author

Kyrtsonis, Marie-Christine, Vassilakopoulos, Theodoros P., Kafasi, Nicoletta, Sachanas, Sotirios, Tzenou, Tatiana, Papadogiannis, Argiroula, Galanis, Zacharoula, Kalpadakis, Christina, Dimou, Maria, Kyriakou, Elias, Angelopoulou, Maria K., Dimopoulou, Maria N., Siakantaris, Marina P., Dimitriadou, Evangelia M., Kokoris, Styliani I., Panayiotidis, Panayiotis, and Pangalis, Gerassimos A.

Published
2007

71. Small Lymphocytic Lymphoma: Analysis of Two Cohorts Including Patients in Clinical Trials of the German Chronic Lymphocytic Leukemia Study Group (GCLLSG) or in Real-Life Outside of Clinical Trials

Author

Sachanas, Sotirios, Pangalis, Gerassimos A., Fink, Anna-Maria, Bahlo, Jasmin, Fischer, Kirsten, Levidou, Georgia, Kyrtsonis, Marie-Christine, Bartzi, Vassiliki, Vassilakopoulos, Theodoros P., Kalpadakis, Christina, Koulieris, Efstathios, Moschogiannis, Maria, Yiakoumis, Xanthi, Tsirkinidis, Pantelis, Angelopoulou, Maria K., Eichhorst, Barbara, Hallek, Michael, Sachanas, Sotirios, Pangalis, Gerassimos A., Fink, Anna-Maria, Bahlo, Jasmin, Fischer, Kirsten, Levidou, Georgia, Kyrtsonis, Marie-Christine, Bartzi, Vassiliki, Vassilakopoulos, Theodoros P., Kalpadakis, Christina, Koulieris, Efstathios, Moschogiannis, Maria, Yiakoumis, Xanthi, Tsirkinidis, Pantelis, Angelopoulou, Maria K., Eichhorst, Barbara, and Hallek, Michael

Abstract

Background: Only few studies have focused exclusively on patients with small lymphocytic lymphoma (SLL). Patients and Methods: In the present report, 103 SLL patients were analyzed from both, clinical trials of the German Chronic Lymphocytic Leukemia Study Group and Greek centers, and emphasis was placed on the therapeutic strategy. The impact of lymph node characteristics, such as the presence of proliferation centers (PCs) on response and survival was also assessed. Results: SLL patients included in clinical trials were treated mostly with fludarabine-based regimens while those in reallife were staged and treated mostly as patients with low-grade lymphomas. Our analysis showed a trend for better survival for patients with SLL without detectable PCs. Conclusion: Patients with SLL outside of clinical trials are usually treated as cases of lymphoma. In addition, this analysis supports published data regarding the adverse prognostic value of the presence of PCs in lymphoid nodes in SLL.

Published
2019

76. Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance

Author

Kalpadakis, Christina, Pangalis, Gerassimos A., Sachanas, Sotirios, Tsirkinidis, Pantelis, Kontopidou, Flora N., Moschogiannis, Maria, Yiakoumis, Xanthi, Koulieris, Efstathios, Dimopoulou, Maria N., Kokkoris, Stella I., Kyrtsonis, Marie-Christine, Siakantaris, Marina P., Tsourouflis, Gerassimos, Korkolopoulou, Penelope, Rontogianni, Dimitra, Tsaftaridis, Panagiotis, Plata, Eleni, Papadaki, Helen A., Panagiotidis, Panagiotis, Angelopoulou, Maria K., and Vassilakopoulos, Theodoros P.

Published
2018
Full Text
View/download PDF

77. Hodgkin's lymphoma in first relapse following chemotherapy or combined modality therapy: analysis of outcome and prognostic factors after conventional salvage therapy

Author

Vassilakopoulos, Theodoros P., Angelopoulou, Maria K., Siakantaris, Marina P., Kontopidou, Flora N., Dimopoulou, Maria N., Boutsis, Dimitrios E., Anargyrou, Konstantinos, Kokoris, Styliani I., Giannakakis, Antonia, Karkantaris, Christos, Kyrtsonis, Marie-Christine, Tsaftaridis, Panayiotis, Rombos, John, Variamis, Eleni, Korkolopoulou, Pinelopi, Kittas, Christos, and Pangalis, Gerassimos A.

Published
2002

78. CD20 Expression in Hodgkin and Reed-Sternberg Cells of Classical Hodgkin’s Disease: Associations With Presenting Features and Clinical Outcome

Author

Rassidakis, George Z., Medeiros, L. Jeffrey, Viviani, Simonetta, Bonfante, Valeria, Nadali, Gian-Paolo, Vassilakopoulos, Theodoros P., Mesina, Ofelia, Herling, Marco, Angelopoulou, Maria K., Giardini, Roberto, Chilosi, Marco, Kittas, Christos, McLaughlin, Peter, Rodriguez, M. Alma, Romaguera, Jorge, Bonadonna, Gianni, Gianni, Alessandro M., Pizzolo, Giovanni, Pangalis, Gerassimos A., Cabanillas, Fernando, and Sarris, Andreas H.

Published
2002

79. The splenic form of mantle cell lymphoma

Author

Angelopoulou, Maria K, Siakantariz, Marina P, Vassilakopoulos, Theodoros P, Kontopidou, Flora N, Rassidakis, George Z, Dimopoulou, Maria N, Kittas, Christos, and Pangalis, Gerassimos A

Published
2002

82. Bone Loss and High Bone Turnover in Patients with Non-Hodgkin's Lymphoma Who Receive Frontline Chemotherapy: Final Results of a Multicenter Prospective Study

Author

Terpos, Evangelos, primary, Fotiou, Despina, additional, Anargyrou, Konstantinos, additional, Vassilakopoulos, Theodoros P., additional, Christoulas, Dimitrios, additional, Makras, Polyzois, additional, Dimou, Maria, additional, Ntanasis-Stathopoulos, Ioannis, additional, Masouridou, Stavroula, additional, Angelopoulou, Maria K., additional, Papatheodorou, Athanasios, additional, Tsionos, Konstantinos, additional, Panayiotidis, Panayiotis, additional, and Dimopoulos, Meletios A., additional

Published
2019
Full Text
View/download PDF

83. Primary Bone Non-Hodgkin's Lymphoma: A Specific Clinical Entity with Aggressive Clinical Course and High Cure Rate - Retrospective Analysis of 102 Patients from Greece

Author

Symeonidis, Argiris, primary, Papageorgiou, Sotirios, additional, Patrinos, Antonis, additional, Melachrinou, Maria, additional, Kourakli, Alexandra, additional, Pappa, Vassiliki, additional, Angelopoulou, Maria K., additional, Sioni, Anastasia, additional, Kanellias, Nikolaos, additional, Chatzileontiadou, Sofia, additional, Hatzimichael, Eleftheria, additional, Zikos, Panagiotis, additional, Pouli, Anastasia, additional, Papaioannou, Maria, additional, Terpos, Evangelos, additional, Pangalis, Gerasimos, additional, and Vassilakopoulos, Theodoros P., additional

Published
2019
Full Text
View/download PDF

84. Low Bone Mineral Density and High Bone Turnover in Patients With Non-Hodgkin's Lymphoma (NHL) Who Receive Frontline Therapy: Results of a Multicenter Prospective Study

Author

Anargyrou, Konstantinos, primary, Fotiou, Despina, additional, Vassilakopoulos, Theodoros P., additional, Christoulas, Dimitrios, additional, Makras, Polyzois, additional, Dimou, Maria, additional, Ntanasis-Stathopoulos, Ioannis, additional, Masouridou, Stavroula, additional, Angelopoulou, Maria K., additional, Papatheodorou, Athanasios, additional, Tsionos, Konstantinos, additional, Panayiotidis, Panayiotis, additional, Dimopoulos, Meletios A., additional, and Terpos, Evangelos, additional

Published
2019
Full Text
View/download PDF

86. Small Lymphocytic Lymphoma: Analysis of Two Cohorts Including Patients in Clinical Trials of the German Chronic Lymphocytic Leukemia Study Group (GCLLSG) or in “Real-Life” Outside of Clinical Trials

Author

SACHANAS, SOTIRIOS, primary, PANGALIS, GERASSIMOS A., additional, FINK, ANNA-MARIA, additional, BAHLO, JASMIN, additional, FISCHER, KIRSTEN, additional, LEVIDOU, GEORGIA, additional, KYRTSONIS, MARIE-CHRISTINE, additional, BARTZI, VASSILIKI, additional, VASSILAKOPOULOS, THEODOROS P., additional, KALPADAKIS, CHRISTINA, additional, KOULIERIS, EFSTATHIOS, additional, MOSCHOGIANNIS, MARIA, additional, YIAKOUMIS, XANTHI, additional, TSIRKINIDIS, PANTELIS, additional, ANGELOPOULOU, MARIA K., additional, EICHHORST, BARBARA, additional, and HALLEK, MICHAEL, additional

Published
2019
Full Text
View/download PDF

87. Central nervous system involvement in primary bone marrow or splenic marginal zone lymphoma: Report of two cases and review of the literature

Author

Angelopoulou, Maria K., primary, Vassilakopoulos, Theodoros P., additional, Konstantinou, Eliana, additional, Boutsikas, George, additional, Asimakopoulos, John V., additional, Triantafyllou, Evangelia‐Faidra, additional, Petevi, Kyriaki, additional, Kanellopoulos, Alexandros, additional, Moschogiannis, Maria, additional, Pangalis, Gerassimos A., additional, Siakantaris, Marina P., additional, and Konstantopoulos, Kostas, additional

Published
2019
Full Text
View/download PDF

88. A Unique Case of Primary Extranodal Marginal Zone Lymphoma of the Anal Canal

Author

Diamantopoulos, Panagiotis, primary, Dryllis, Georgios, additional, Tsourouflis, Gerasimos, additional, Petevi, Kyriaki, additional, Boutsikas, Georgios, additional, Rondogianni, Phoebe, additional, Boutsis, Dimitris, additional, Korkolopoulou, Penelope, additional, Konstantopoulos, Konstantinos, additional, Angelopoulou, Maria K., additional, Meletis, John, additional, Kanellis, George, additional, and Vassilakopoulos, Theodoros P., additional

Published
2019
Full Text
View/download PDF

89. BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens

Author

Rassidakis, George Z., Medeiros, L. Jeffrey, Vassilakopoulos, Theodoros P., Viviani, Simonetta, Bonfante, Valeria, Nadali, Gianpaolo, Herling, Marco, Angelopoulou, Maria K., Giardini, Roberto, Chilosi, Marco, Kittas, Christos, McDonnell, Timothy J., Bonadonna, Gianni, Gianni, Alessandro M., Pizzolo, Giovanni, Pangalis, Gerassimos A., Cabanillas, Fernando, and Sarris, Andreas H.

Published
2002
Full Text
View/download PDF

90. Successful salvage of primary progressive Hodgkin lymphoma with the combination of post‐transplant brentuximab vedotin and radiotherapy: Combining novelty and tradition.

Author

Belia, Marina, Chatzidimitriou, Chrysovalantou, Rondogianni, Phivi, Petsa, Panayiota, Efstathopoulou, Maria, Konstantinou, Eliana, Arapaki, Maria, Asimakopoulos, John, Plata, Eleni, Konstantopoulos, Kostas, Angelopoulou, Maria K., and Vassilakopoulos, Theodoros P.

Subjects
HODGKIN'S disease, COMPUTED tomography, PROGNOSIS
Abstract

Keywords: autologous transplantation; brentuximab vedotin; Hodgkin lymphoma; primary refractory; radiotherapy EN autologous transplantation brentuximab vedotin Hodgkin lymphoma primary refractory radiotherapy 258 262 5 04/15/21 20210401 NES 210401 PEER REVIEW The peer review history for this article is available at https://publons.com/publon/10.1002/hon.2801. While receiving BV consolidation, the patient underwent RT (36 Gy at the initially involved field plus 10 Gy at persistent disease) and a CR was demonstrated post-RT (Figure 1F). A multi-Institutional analysis of peritransplantation radiotherapy in patients with relapsed/refractory Hodgkin lymphoma undergoing autologous stem cell transplantation. Pembrolizumab monotherapy in patients with primary refractory classical Hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 Subgroup Analysis. [Extracted from the article]

Published
2021
Full Text
View/download PDF

92. Curative surgery in highly selected patients with heavily pretreated, relapsed/refractory classical Hodgkin lymphoma.

Author

Papadakis, Vassilios, Efstathopoulou, Maria, Angelopoulou, Maria K., Tsourouflis, Gerassimos, Prassopoulos, Vassilios, Rondogianni, Phivi, Kourtesis, Antonios, Polychronopoulou, Sophia, Pangalis, Gerassimos A., and Vassilakopoulos, Theodoros P.

Subjects
HODGKIN'S disease, HEMATOPOIETIC stem cell transplantation, COMPUTED tomography, SOLITARY pulmonary nodule
Abstract

PET/CT was not performed prior to surgery but the localized nature of the lesion was confirmed by the negative post-surgery PET/CT after the complete resection of the lesion, which had been transformed to anaplastic large cell lymphoma (ALK-negative). It is important to note that there were no other patients within the two cohorts of pediatric and adult cHL patients with 9 and 410 relapsed/refractory cases respectively, in whom a surgery-only approach was applied and failed. At least 70-80% of the patients with Hodgkin lymphoma (HL) can be cured with first-line therapy with the improvement of staging methods and the introduction of increasingly effective chemotherapy regimens during the last 50 years [[1]]. [Extracted from the article]

Published
2021
Full Text
View/download PDF

95. Study of bone metabolism and angiogenesis in patients undergoing high-dose chemotherapy/autologous hematopoietic stem cell transplantation

Author

Boutsikas, Georgios, primary, Terpos, Evangelos, additional, Papatheodorou, Athanasios, additional, Tsirkinidis, Pantelis, additional, Tsirigotis, Panayiotis, additional, Meletiou, Anastasia, additional, Lalou, Eleni, additional, Telonis, Vasileios, additional, Zannou, Anna, additional, Kanellopoulos, Alexander, additional, Galani, Zacharoula, additional, Stefanou, Angeliki, additional, Tsaftaridis, Panayiotis, additional, Viniou, Nora-Athina, additional, Panayiotidis, Panayiotis, additional, Kyrtsonis, Marie-Christine, additional, Meletis, John, additional, Vassilakopoulos, Theodoros P., additional, and Angelopoulou, Maria K., additional

Published
2017
Full Text
View/download PDF

96. Bone metabolism markers and angiogenic cytokines as regulators of human hematopoietic stem cell mobilization

Author

Tsirkinidis, Pantelis, primary, Terpos, Evangelos, additional, Boutsikas, Georgios, additional, Papatheodorou, Athanasios, additional, Anargyrou, Konstantinos, additional, Lalou, Eleni, additional, Dimitrakopoulou, Aglaia, additional, Kalpadakis, Christina, additional, Konstantopoulos, Konstantinos, additional, Siakantaris, Marina, additional, Panayiotidis, Panayiotis, additional, Pangalis, Gerassimos, additional, Kyrtsonis, Marie-Christine, additional, Vassilakopoulos, Theodoros, additional, and Angelopoulou, Maria K., additional

Published
2017
Full Text
View/download PDF

97. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience

Author

Angelopoulou, Maria K., primary, Vassilakopoulos, Theodoros P., additional, Batsis, Ioannis, additional, Sakellari, Ioanna, additional, Gkirkas, Konstantinos, additional, Pappa, Vasiliki, additional, Giannoulia, Panagiota, additional, Apostolidis, Ioannis, additional, Apostolopoulos, Christos, additional, Roussou, Paraskevi, additional, Panayiotidis, Panayiotis, additional, Dimou, Maria, additional, Kyrtsonis, Marie-Christine, additional, Palassopoulou, Maria, additional, Vassilopoulos, Georgios, additional, Moschogiannis, Maria, additional, Kalpadakis, Christina, additional, Margaritis, Dimitrios, additional, Spyridonidis, Alexander, additional, Michalis, Eurydiki, additional, Anargyrou, Konstantinos, additional, Repousis, Panagiotis, additional, Hatzimichael, Eleutheria, additional, Bousiou, Zoi, additional, Poulakidas, Elias, additional, Grentzelias, Dimitrios, additional, Harhalakis, Nikolaos, additional, Pangalis, Gerassimos A., additional, Anagnostopoulos, Achilles, additional, and Tsirigotis, Panagiotis, additional

Published
2017
Full Text
View/download PDF

98. Prognostic factors in Hodgkin lymphoma

Author

Broeckelmann, Paul J., Angelopoulou, Maria K., Vassilakopoulos, Theodoros P., Broeckelmann, Paul J., Angelopoulou, Maria K., and Vassilakopoulos, Theodoros P.

Abstract

During the last decades, the prognosis of Hodgkin lymphoma (HL) has been improved significantly with the introduction of effective chemotherapy and the implementation of risk-adapted treatment approaches. Identification of reliable risk factors is crucial to guide treatment over the course of disease. Both clinical and biological factors have been implicated in the prognosis of HL and are often used in prognostic scores to discriminate risk groups. To prevent under- or overtreatment, patients are usually assigned to one of the three widely established risk groups for first-line treatment, based solely on clinical risk factors. To further individualize therapeutic approaches, functional imaging with positron emission tomography (PET) is becoming more widely implemented and precisely investigated within clinical trials. Biological prognostic factors have been widely evaluated but are still not a part of standard prognostication. This review will discuss the currently established factors and risk models at first diagnosis and in the setting of relapsed/refractory disease and also focus on biological factors and PET, summarizing current standards and future perspectives. (C) 2016 Elsevier Inc. All rights reserved.

Published
2016

100. New Insights in the Mobilization of Hematopoietic Stem Cells in Lymphoma and Multiple Myeloma Patients

Author

Angelopoulou, Maria K., Tsirkinidis, Pantelis, Boutsikas, Georgios, Vassilakopoulos, Theodoros P., and Tsirigotis, Panayiotis

Subjects
Article Subject
Abstract

Following chemotherapy and/or the administration of growth factors, such as granulocyte-colony stimulated factor (G-CSF), hematopoietic stem cells (HSC) mobilize from bone marrow to peripheral blood. This review aims to systematically present the structure of the HSC “niche” and elucidate the mechanisms of their mobilization. However, this field is constantly evolving and new pathways and molecules have been shown to contribute to the mobilization process. Understanding the importance and the possible primary pathophysiologic role of each pathway is rather difficult, since they share various overlapping components. The primary initiating event for the mobilization of HSC is chemotherapy-induced endogenous G-CSF production or exogenous G-CSF administration. G-CSF induces proliferation and expansion of the myelomonocytic series, which leads to proteolytic enzyme activation. These enzymes result in disruption of various receptor-ligand bonds, which leads to the disanchorage of HSC from the bone marrow stroma. In everyday clinical practice, CXC chemokine receptor-4 (CXCR4) antagonists are now being used as mobilization agents in order to improve HSC collection. Furthermore, based on the proposed mechanisms of HSC mobilization, novel mobilizing agents have been developed and are currently evaluated in preclinical and clinical studies.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results